Cellectis (NASDAQ:CLLS) Lowered to Hold Rating by StockNews.com

Cellectis (NASDAQ:CLLS) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Cellectis Trading Down 3.1 %

Shares of NASDAQ:CLLS opened at $1.27 on Wednesday. The stock has a market capitalization of $70.59 million, a PE ratio of -0.98 and a beta of 3.27. Cellectis has a 1 year low of $1.14 and a 1 year high of $3.38. The firm has a fifty day moving average price of $1.46 and a 200 day moving average price of $1.79. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.22). The business had revenue of $33.22 million during the quarter, compared to the consensus estimate of $5.90 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. Analysts expect that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its position in Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 12,500 shares in the last quarter. Millennium Management LLC bought a new stake in Cellectis during the fourth quarter worth about $962,000. Finally, B Group Inc. bought a new stake in Cellectis during the fourth quarter worth about $5,547,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.